Jounce Therapeutics (NASDAQ:JNCE) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.32) by 84.37 percent. This is a 168.6 percent decrease over earnings of $0.86 per share from the same period last year.
The RealReal’s Return On Capital Employed Insights
The RealReal (NASDAQ:REAL) brought in sales totaling $146.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 10.0%, resulting in a loss of $57.41 million.
